Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HUTCHMED (China)HMDCF 64 Days Payable is 48.26 as of Dec. 2025, which is 14% below its 10-year median of 55.97. GuruFocus rates HMDCF with a GF Score™ of 64/100 and a GF Value™ of $3.76 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 927 Drug Manufacturers companies, HUTCHMED (China) ranks worse than 75.73% on this metric.
The historical rank and industry rank for HUTCHMED (China)'s Days Payable or its related term are showing as below:
HMDCF'
s Days Payable Range Over the Past 10 Years
Min: 41.22 Med: 55.97 Max: 64.94
Current: 48.69
During the past 13 years, HUTCHMED (China)'s highest Days Payable was 64.94. The lowest was 41.22. And the median was 55.97.
HMDCF's Days Payable is ranked worse than 75.73% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs HMDCF: 48.69
HUTCHMED (China)'s Days Payable
increased
from Dec. 2024 (46.46) to Dec. 2025 (48.26).
It may suggest that HUTCHMED (China)delayed paying its suppliers.
HUTCHMED (China) Days Payable Related Terms
HUTCHMED (China) Days Payable Historical Data
* Premium members only.
The historical data trend for HUTCHMED (China)'s Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HUTCHMED (China) Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s Days Payable distribution charts can be found below:
* The bar in red indicates where HUTCHMED (China)'s Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
HUTCHMED (China)'s Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HUTCHMED (China) (HMDCF) has a Days Payable of 48.26 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HUTCHMED (China) and its competitors. This is 14% below median its historical median of 55.97. Over the past decade, HUTCHMED (China)'s Days Payable has ranged from 41.22 to 64.94. According to the industry distribution chart, HUTCHMED (China) ranks #702 out of 927 companies in the Drug Manufacturers industry, placing it in the top 75.7%.
Is HUTCHMED (China)'s Days Payable too high?
HUTCHMED (China)'s current Days Payable of 48.26 is 14% below median its 10-year median of 55.97. Over the past 10 years, this metric has ranged from a low of 41.22 to a high of 64.94. The Drug Manufacturers industry median Days Payable is 90.38. HUTCHMED (China)'s value of 48.26 is 46.6% below this industry median. Based on the distribution chart, HUTCHMED (China) ranks #702 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, HUTCHMED (China) has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #702 out of 927 companies for Days Payable. This places HUTCHMED (China) in the lower half of its industry. The industry median Days Payable is 90.38. HUTCHMED (China)'s value of 48.26 is 46.6% below this benchmark. Historically, HUTCHMED (China)'s own Days Payable has ranged from 41.22 to 64.94 over the past decade. While the company's 10-year median is 55.97 vs. the industry median of 90.38, HUTCHMED (China) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HUTCHMED (China)'s current Days Payable of 48.26 is 46.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current Days Payable is 48.26, which is 14% below median its own 10-year median of 55.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
Based on GuruFocus' analysis, HUTCHMED (China) (HMDCF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.76, compared to a current price of $2.16 — trading 42.6% below its estimated fair value. The current Days Payable is 48.26, which is 14% below median its 10-year median of 55.97 and 46.6% below the Drug Manufacturers industry median of 90.38. HUTCHMED (China)'s overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For HUTCHMED (China) (HMDCF), the current Days Payable is 48.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HUTCHMED (China) (HMDCF) Overvalued in 2026?
Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued.
The current stock price of $2.16 is trading 42.6% below its estimated GF Value™ of $3.76.
GuruFocus considers HUTCHMED (China) to be Possible Value Trap.
Key valuation signals for HMDCF:
Days Payable: 48.26 (14% below median its 10-year median of 55.97)
GF Value™: $3.76 vs. price of $2.16 (42.6% below fair value)
Industry Position: 46.6% below the Drug Manufacturers median (#702 of 927)
No single metric tells the full story. See the HMDCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
64GF Score
Get the complete analysis for HMDCF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HMDCF has been successfully added to your 
